<DOC>
	<DOCNO>NCT01631942</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) NNC 0172-2021 administer subcutaneously healthy male subject subject haemophilia .</brief_summary>
	<brief_title>A Multi-centre , Open Labelled , Multiple Dosing Trial Investigating Safety , Pharmacokinetics Pharmacodynamics NNC 0172-2021 Administered Subcutaneously Healthy Male Subjects Haemophilia Subjects</brief_title>
	<detailed_description>The present phase 1 trial terminate due need change trial design require new re-designed multiple dose phase 1 trial . Initiation new trial awaits additional non-clinical data .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>For haemophilia subject : Subjects diagnose haemophilia A baseline level Factor VIII Factor IX 2 % without inhibitor Known suspect hypersensitivity trial product ( ) relate product Thrombocyte count lower limit normal range screen Any clinical sign know history thromboembolic event , subject consider high risk thromboembolic event judge investigator subject increase risk cardiovascular disease judge investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>